drugset / Trial / NCT00222521

Insulin Glargine Vs Standard Insulin Therapy

NCT00222521

RandomizedCrossoverOpen-labelTreatment

Summary

This Study is designed to determine whether treatment of CFRD with glargine insulin will improve hemoglobin A1c, weight and muscle mass compared to the traditional regimen of bedtime NPH insulin.

Timeline

Start
2003-04
Primary completion
Completion
2005-08

Drugs

EvaluationDrugModalityDoseRoute
Subject insulin glargine Protein / enzyme biologic